



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 236 822

A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87102448.5

(51) Int. Cl. 3: A 61 K 31/135
A 61 K 47/00

(22) Date of filing: 20.02.87

(30) Priority: 07.03.86 US 837243

(43) Date of publication of application:
16.09.87 Bulletin 87/38

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI NL SE

(71) Applicant: AMERICAN CYANAMID COMPANY
1937 West Main Street P.O. Box 60
Stamford Connecticut 06904-0060(US)

(72) Inventor: Niphadkar, Pradeep V.
201 Randolph Avenue
Clifton New Jersey 07011(US)

(72) Inventor: Desai, Narendra R.
Hollcroft Apts. 11H Clapboard Ridge Road
Danbury Connecticut 06810(US)

(72) Inventor: Jones, Paul N.
792 Brookridge Drive
Valley Cottage New York 10989(US)

(72) Inventor: Mooney, Kieran G.
30 Clinton Avenue
Warwick New York 10990(US)

(74) Representative: Wächtershäuser, Günter, Dr.
Taiz
D-8000 München 2(DE)

(54) Stable injectable pharmaceutical formulation for
1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride.

(57) This disclosure describes stable injectable pharmaceutical formulations of NOVANTRONE®.

EP 0 236 822 A2

0,292


- 1 -

0236822

Title: STABLE INJECTABLE PHARMACEUTICAL
FORMULATION FOR 1,4-DIHYDROXY-
5,8-BIS[2-(2-HYDROXYETHYLAMINO)-
ETHYLAMINO]ANTHRAQUINONE,
DIHYDROCHLORIDE

DESCRIPTION OF THE INVENTION

The compound 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride, having the formula:



is described and claimed in U. S. Patent No. 4,197,249 and is sold under the registered trademark Novantrone[®] in Canada and Europe and is currently under consideration by the United States Food and Drug Administration for approval as an anti-cancer agent.

0236822

- 2 -

This compound is known to undergo oxidative degradation in aqueous solution. This degradation occurs much more rapidly in the presence of metal ions such as cuprous, cupric, ferrous, ferric, etc., even when present in minute quantities (e.g. less than 10 ppm).

Since this compound exhibits optimum pharmacological activity in humans when administered parenterally (intramuscularly, intravenously) as opposed to oral administration, it is extremely important that solutions of this compound remain stable for prolonged periods under normal storage conditions.

It has now been discovered that the inclusion of a combination of critical factors in an aqueous formulation of 1,4-dihydroxy-5,8-bis[2-(hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride provides a formulation which is extremely stable under normal storage conditions.

These factors are 1) the inclusion of a suitable antioxidant, 2) specific pH range, and 3) the inclusion of a suitable metal ion chelator.

With regard to antioxidants the most effective proved to be sodium metabisulfite.

The most effective pH range was 2.0-3.5 with 3.0 being optimum.

The most effective metal ion chelator was a combination of disodium EDTA and glycine.

- 3 -

0236822

Since the desired injectable formulation of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride contains 1 to 5 mg of this compound per ml of formulation, this new stable formula would have a pH of 2.0 to 3.5, with 3.0 being optimal, a sodium metabisulfite concentration of 0.01 to 0.10%, with 0.05% being optimal, disodium EDTA at a concentration of 0.01 to 0.11% with 0.10% being optimal, and glycine concentration of 0.05 to 0.2% with 0.1% being optimal.

In order to prove the enhanced stability of this new formulation, formulae of the following composition were prepared and stability studies conducted.

Formula I

| | |
|---|---------|
| 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride..... | 2 mg/ml |
| Water for Injection U.S.P. | 100% |
| Headspace..... | Air |

Formula II

| | |
|---|---------|
| 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride..... | 2 mg/ml |
| Cupric ions..... | 7 ppm |
| Water for Injection U.S.P. | 100% |
| Headspace..... | Air |
| pH..... | 5.50 |

0236822

- 4 -

Formula III

| | |
|--|----------|
| 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride..... | 2 mg/ml |
| Sodium metabisulfite..... | 0.01% |
| Sodium acetate..... | 0.005% |
| Acetic acid, glacial..... | 0.046% |
| Sodium chloride..... | 0.80% |
| Water for Injection U.S.P. | 100% |
| pH..... | 3.5 |
| Headspace..... | Nitrogen |

Formula IV

| | |
|--|---------------|
| 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride..... | 2 mg/ml |
| Sodium metabisulfite..... | 0.05% |
| Disodium EDTA..... | 0.10% |
| Glycine..... | 0.10% |
| Sodium chloride (Isotonic Agent)..... | 0.786% |
| Water for Injection U.S.P. | 100% |
| pH..... | 3.0 |
| Headspace..... | as indicated* |

*One portion filled under nitrogen, two portions filled
under air.

The results of these stability studies are
given below:

0236822

-5-

| Formula | Vial Size | Headspace Temp. °C | % of Initial Potency | | | | |
|---------|-----------|--------------------|----------------------|---------|---------|---------|---------|
| | | | 1 Day | 2 Weeks | 3 Weeks | 4 Weeks | 8 Weeks |
| I | 10 ml | Air | 56 | 13 | 88 | 84.5 | 72 |
| II | 10 ml | Air | 56 | 13 | 85 | 90 | 90 |
| III | 10 ml | Nitrogen | 56 | 42 | 96 | 93 | 93 |
| III | 2 ml | Nitrogen | 56 | 85 | 72 | 72 | 72 |
| IV | 2 ml | Nitrogen | 56 | 99 | 98.6 | 97.9 | 97.9 |
| IV | 10 ml | Nitrogen | 42 | 98 | 97.6 | 97.6 | 97.6 |
| IV | 10 ml | Air | 56 | 42 | 98 | 97.5 | 97.5 |
| V | 10 ml | Nitrogen | 56 | 99 | 98 | 98.4 | 98.4 |

- 6 -

0236822

The above results show the superiority of the new formulation of this invention over the previous formulation and an aqueous solution of this drug.

Like most other anticancer drugs, the dose of Novantrone® is based upon the patient's body surface area and disease state. It is highly advantageous from cost and marketing point of views to have Novantrone® product available in small size containers like 2 ml vials. However, because of relatively higher headspace to volume ratio of smaller vials as against the larger vials, the stability of this product becomes critical in small 2 ml vials. It is important to note that the new formulation was found to be superior to the previous formulation in both small as well as relatively larger volume vials.

To further illustrate the stability of this invention a composition was prepared as follows.

0236822

- 7 -

Formula V

1,4-Dihydroxy-5,8-bis[2-(2-hydroxy-
ethylamino)ethylamino]anthraquinone,
dihydrochloride..... 2 mg/ml
Disodium EDTA..... 0.10%
Sodium metabisulfite..... 0.04%
Glycine..... 0.10%
Sodium chloride (Isotonic Agent)..... 0.60%
Water for Injection U.S.P. 100%
pH 3.0

This formula (V) and a composition of formula (I) each had cupric ions added to a concentration of 6 ppm and were then placed in a stability study at 56°C for 4 weeks. The results at the end of this time showed that formula (I) lost 98% of its potency in 2 days while formula (V) retained 98.6% potency after 4 weeks.

- 8 -

0236822

CLAIMS

We claim:

1. A pharmaceutical formulation comprising from 1 to 5 mg per ml of formulation of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride in an isotonic solution at a pH of from 2.0 to 3.5, containing sodium metabisulfite at a concentration of from 0.01 to 0.10%, disodium EDTA at a concentration of from 0.01 to 0.11% and glycine at a concentration of from 0.05 to 0.20%.

2. A formulation according to Claim 1 where the concentration of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride is 2 mg/ml and the concentrations of sodium metabisulfite, disodium EDTA and glycine are 0.05%, 0.10% and 0.10% respectively.